Intellia Therapeutics/$NTLA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Ticker

$NTLA
Sector
Primary listing

Employees

403

NTLA Metrics

BasicAdvanced
$2.1B
-
-$4.68
2.32
-

What the Analysts think about NTLA

Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.

Bulls say / Bears say

As of June 30, 2025, Intellia held $630.5 million in cash, cash equivalents and marketable securities, providing a runway into the first half of 2027 and supporting continued development of its late-stage CRISPR programs. (Nasdaq)
Intellia’s collaboration revenue more than doubled year-over-year in Q2 2025 to $14.2 million, beating analyst estimates of $11.9 million and underscoring strong partner support, notably from its alliance with Regeneron. (Nasdaq)
Enrollment in Intellia’s global Phase 3 trials is tracking ahead of projections, with the MAGNITUDE study on course to enroll at least 650 patients by year-end and HAELO randomization expected to complete in Q3 2025, highlighting robust operational execution. (GlobeNewswire)
Intellia reported a GAAP net loss of $101.3 million (-$0.98 per share) in Q2 2025, reflecting continued unprofitability despite operational progress and highlighting the challenge of reaching profitability without product revenue. (Nasdaq)
Collaboration revenue of $14.2 million in Q2 2025 remains insufficient to cover significant R&D and G&A expenses, underlining Intellia’s reliance on external partnerships and future financing to sustain its development programs. (Nasdaq)
Despite recent gains, Intellia’s Relative Strength Rating stands at 76, below the 80 threshold common among breakout stocks, and the shares rank 267th in the Medical-Biomed/Biotech industry, indicating limited technical momentum. (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

NTLA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NTLA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTLA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs